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Abstract Satisfaction with medication is important in the
evaluation of overall treatment outcome. There is a lack of
consistent and validated rating scales for satisfaction with
medication in ADHD, therefore comparison across studies is
difﬁcult. Here, we analyse the psychometric properties of the
satisfactionwithmedicationscale(SAMS),anewitem-based
questionnaire that assesses satisfaction with ADHD medica-
tion.Furthermore,weevaluatethepredictiveeffectofADHD
symptoms and quality of life (QoL) on satisfaction. Data on
satisfaction with Equasym XL
 (methylphenidate) were
collected in the OBSEER study using the parent (SAMS-P,
n = 589) and patient (SAMS-S, n = 552) versions of the
SAMS questionnaire. Internal consistency, item-total and
cross-informant correlations, and the stability of satisfaction
ratings overtime wereassessed. Satisfaction withmedication
scores were then correlated with ratings of ADHD symptoms
and QoL. Rates of overall satisfaction with Equasym XL

amongparentsandchildrenwerehigh([70%),aswasinternal
consistency for both SAMS-P and SAMS-S (Cronbach’s
alpha[0.9). Similarly, item-total correlations were high
(r = 0.71–0.90) for SAMS-P and medium–high (r = 0.57–
0.77) for SAMS-S. Cross-informant correlations and the sta-
bility of satisfaction ratings were moderate (r = 0.54–0.59
and 0.48–0.60, respectively). ADHD symptom and QoL rat-
ings were signiﬁcantly negative and positive predictors of
satisfaction,explaining36–52%ofsatisfactionvarianceatthe
ﬁnalvisit.Theresultsshowthatparentandpatientsatisfaction
was high and could be assessed reliably with the new SAMS
questionnaire. Parent and patient ratings were moderately
correlated, and symptom severity, functional impairment and
QoL were the most signiﬁcant predictors of satisfaction.
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Introduction
Attention deﬁcit hyperactivity disorder (ADHD) is the most
common mental health condition among children and ado-
lescents, with a worldwide prevalence of over 5% [22].
Pharmacological therapies such as stimulant medications
have proven to be effective in helping control both ADHD
core symptoms (inattention, hyperactivity and impulsivity)
and the behavioural problems associated with the disease
(e.g. aggressive behaviour, depressive mood, anxiety, tics,
impaired social functioning and academic productivity) in
affected children [2]. Over the past few years, several new
medications for ADHD have become available, many of
which are modiﬁed, long-acting formulations of stimulants
(i.e.methylphenidate[MPH]andamphetamine)developedto
eliminate the need for multiple doses during the day, thus
reducing the adherence issues that multiple dosing can cause
[15].EquasymXL
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DOI 10.1007/s00787-011-0207-zis a long-acting MPH formulation that combines 30%
immediate-release(IR)and70%modiﬁed-release(MR)MPH
and has beenshowntobeaseffective astwice-dailyMPH-IR
[13].
Patient satisfaction with medication is an important
factor in the evaluation of overall treatment outcome.
Although improvement of symptoms is the main aim,
treatments cannot be considered effective in real life if they
are not accepted and patients are not willing to use them
[5]. Satisfaction with medication is considered to be pre-
dictive of better adherence and compliance to treatment,
and to prevent premature treatment termination [20]. It is
inﬂuenced by several determinants, including treatment
effectiveness, consumer expectations, demographic char-
acteristics, social validity or acceptability of the treatment
and provider factors, such as patient–physician bonding
and the physician’s knowledge, competence and ability to
communicate with patients and their families. The cultural
setting can also deeply affect satisfaction and the percep-
tion of treatment, as it shapes patients’ beliefs and their
reactions to symptoms [5].
Measuring the satisfaction with medication of children
or adolescents with ADHD, their parents and teachers can
help identify expectations and deﬁne therapies that are
most appropriate; this is of particular interest in the case of
ADHD given the diversity of effective treatment options
offered [18]. Unfortunately, data in the literature are lim-
ited, and satisfaction measures are rarely included in study
protocols. Despite the effectiveness of ADHD medications,
parents and teachers generally consider non-pharmacolog-
ical or combination (pharmacological and non-pharmaco-
logical) therapies more acceptable [17, 19, 23], which can
clearly have an inﬂuence on the way children perceive
medication [28]. However, satisfaction with stimulant
medication alone is relatively high, with 63–87% of
patients, parents and teachers making positive assessments
[7, 10, 11, 28, 29]. Results from a recent qualitative UK
study commissioned by the National Institute for Health
and Clinical Excellence (NICE) ADHD guideline group in
16 young (9- to 14-year-old) people with ADHD treated
with stimulants also indicate that stimulant medication is
generally perceived as beneﬁcial by patients, particularly
for social relationships, and that those who are already
taking stimulants are more positive about medication than
other types of intervention [26].
The available evidence from the trials of ADHD medi-
cations does not demonstrate higher satisfaction with a
particular drug class [5], although there are indications of a
preference for long-acting formulations. In a double-blind
comparison of a long-acting MPH formulation (osmotic
release oral system [OROS] MPH [Concerta, Janssen-Cilag
Ltd]) given once-daily versus three-times-daily MPH-IR,
47% of parents preferred the long-acting formulation, 31%
the IR formulation, and 15% their previous MPH treatment
[21]. Similarly, in an 8-week open-label study of the same
long-acting formulation, 50% of parents were ‘completely
satisﬁed’ with it, compared with 21% with MPH-IR given
two or three times daily [27]. Another 1-year open-label
study of OROS MPH reported that 50% of parents/care-
givers and 75% of investigators evaluated the treatment
positively, which may reﬂect the longer duration of
symptom control [14]. Finally, in a post-marketing study of
the 30:70 combination of IR and MR MPH of which
Equasym XL
 consists, 84.6% of patients previously
treated with MPH-IR and 59.4% of those previously treated
with a different long-acting formulation rated the study
medication better or much better than their prior treatment
[7].
Although several measures of satisfaction with medi-
cation have been used for ADHD, for example the medi-
cation satisfaction questionnaire (MSS) [6] or the parent
consumer satisfaction questionnaire (PCSQ) [16], clinical
trials do not generally apply the same methodological
rigour to satisfaction measures as they do to other out-
comes. The assessment of satisfaction is often reduced to
asking children, parents or teachers how satisﬁed they are
with a speciﬁc medication, usually at a low level of detail.
One of the main limitations when considering satisfaction
with medication in ADHD is the lack of consistent, uni-
form and validated rating scales for satisfaction that enable
comparison across studies [5].
In this paper, we analyse the psychometric properties
(validity and reliability) of the satisfaction with medication
scale (SAMS), a new rating scale designed to assess the
satisfaction with ADHD medication of parents and chil-
dren on a per item basis. We report data on satisfaction
with Equasym XL
 collected using this scale in the OB-
SEER (OBservation of Safety and Effectiveness of Equ-
asym XL
 in Routine care) study [8]. We correlate these
data with ratings of ADHD symptoms by physicians,
teachers and parents [8], and with ratings of quality of life
(QoL) by patients and parents [25] collected during and at
the end of the OBSEER study, evaluating the predictive
effect of such ratings on patient and parent satisfaction
with medication.
Methods
Participants and study design
OBSEER was a post-marketing observational study of
Equasym XL
, primarily designed to assess the effective-
ness and safety in clinical practice, conducted in 169
centres in Germany in accordance with local regulations
and under the therapeutic responsibility of the attending
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was not required for this study. The study included children
aged 6–17 years with a conﬁrmed diagnosis of ADHD
according to the Diagnostic and Statistical Manual of the
American Psychiatric Association (DSM-IV-TR) [1]o r
hyperkinetic disorder (HKD) according to the International
Classiﬁcation of Diseases (ICD-10) [30], for whom therapy
with Equasym XL
 was already planned by the treating
physician. Details regarding study design, participants,
effectiveness of Equasym XL
 and safety proﬁle are
described elsewhere in this supplement [8].
Outcome measures
Satisfaction with medication
In the OBSEER study, satisfaction with medication was
assessed using the SAMS tool at baseline (Visit 1), in a
follow-up visit 1–3 weeks after the ﬁrst use of Equasym
XL
 (Visit 2) and at a ﬁnal visit 6–12 weeks after the ﬁrst
use of Equasym XL
 (Visit 3). This paper analyses the
satisfaction with medication as measured at Visit 3.
SAMS is a newly designed questionnaire for the
assessment of satisfaction with medication and consists of
12 items, which are scored on a six-point scale with values
from 1 to 6. High values indicate positive attitudes to drug
therapy, and low values indicate negative attitudes (1 =
strongly disagree; 2 = disagree; 3 = slightly disagree; 4 =
slightly agree; 5 = agree; 6 = strongly agree); a score of 5
or 6 was classiﬁed as high satisfaction.
The ﬁrst 11 items evaluate satisfaction with the effects of
the medication on the following aspects: (1) behaviour of the
child, (2) ability to pay attention, (3) reduction of hyperac-
tivity, (4) ability to sustain attention and stick to tasks, (5)
ability to cope better with homework assignments and other
tasks,(6)abilitytogetalongwithother children,(7)abilityto
get along with family, (8) ability to get along at school, (9)
onset of medication effect in the morning, (10) duration of
medication effect and (11) general well-being. Item 12
assesses the overall satisfaction with the medication. Two
versionsoftheSAMSquestionnairehavebeendeveloped:the
parent report form (SAMS-P), which assesses parent satis-
faction withtheir child’s medication, and the self-report form
(SAMS-S), which assesses patient satisfaction. Both forms
include the same items, but questions are phrased differently
and adapted for parents and children (see Tables 1 and 2 for
the exact wording). The total score of each rating scale is the
sumofthescoresofthedifferentitemsdividedbythenumber
of items and also ranges from 1 to 6.
Other measures
Satisfaction with medication measures were correlated
with measures of ADHD symptoms and QoL from the
OBSEER study, which were obtained using the following
tools.
1. German ADHD symptom checklist (Fremdbeurtei-
lungsbogen fu ¨r Aufmerksamkeitsdeﬁzit-Hyperakti-
vita ¨tssto ¨rung, FBB-ADHD) [4, 9, 12]: FBB-ADHD is
part of the German diagnostic system for mental
Table 1 Item statistics for parent satisfaction (SAMS-P, n = 589)
Item Mean SD Parents expressing
high satisfaction (%)
Item-total
correlation
1 I am satisﬁed with how my child behaves while taking this medication 4.80 1.18 71.30 0.85
2 I am satisﬁed with how this medication helps my child to pay attention 4.88 1.14 75.60 0.89
3 I am satisﬁed with how this medication helps my child getting less hyperactive 4.73 1.22 70.80 0.80
4 I am satisﬁed with how this medication helps my child sustain attention
and stick to tasks
4.84 1.13 72.20 0.87
5 I am satisﬁed with how this medication helps my child cope better
with homework assignments and other tasks
4.66 1.20 64.30 0.84
6 I am satisﬁed with how this medication helps my child get along with other kids 4.61 1.24 64.30 0.68
7 I am satisﬁed with how this medication helps my child get along with my family 4.57 1.23 63.00 0.77
8 I am satisﬁed with how this medication helps my child to get along at school 4.83 1.14 73.00 0.82
9 I am satisﬁed with the onset of the medication’s effect in the morning 4.80 1.15 73.00 0.71
10 I am satisﬁed with the duration of the medication’s effect 4.42 1.32 57.60 0.79
11 I am satisﬁed with how this medication helps my child feel good 4.42 1.32 57.60 0.79
12 Overall, I am satisﬁed with the medication 4.70 1.24 70.50 0.90
Total score (sum of item scores/12) 4.69 1.02 – –
SAMS Satisfaction with medication scale, SD Standard deviation
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123disordersinchildrenandadolescents(DISYPS-II)[9]and
assesses 20 symptom items, which are rated by teachers
and parents on a scale ranging from 0 = not at all to
3 = very much, with higher scores indicating more
severe symptoms. Nine symptom items are combined
into a subscale assessing inattention and 11 items are
combined to assess hyperactivity and impulsivity; the
total symptom score covers all 20 symptom items. In
addition, four items evaluate functional impairment with
respect to school performance, relationship towards
adults and children and the subjective level of suffering
(functional impairment subscale), and six items assess
competences regarding attentive, reﬂexive and enduring
behaviour (attention–reﬂexivity subscale).
2. ADHD-Clinical Global Impression-Severity (ADHD-
CGI-S) and ADHD-Clinical Global Impression-
Improvement (ADHD-CGI-I) scales, assessing ADHD
core symptoms (inattention, hyperactivity and impul-
sivity) and disease-associated problems (aggressive
behaviour, depressive mood, anxiety, tics and learning
difﬁculties).
3. DayproﬁleofADHDsymptoms(DAYAS)[3]:DAYAS
assesses the daily proﬁle of ADHD and other external-
ising symptoms from early morning until bedtime. A
teacher versionofthe questionnaire (DAYAS-T) consid-
erstheﬁrstandsecondpartofthemorningatschool.This
complements the parent version (DAYAS-P), which
covers the remaining four daily periods: early morning
(before school), early afternoon until 4.00 pm, late
afternoon until 7.00 pm and evening. The rating scale
evaluates six items: (1) hyperactivity, (2) inattention, (3)
impulsivity, (4) oppositional behaviour, (5) aggressive
behaviour and temper tantrums and (6) a global rating of
problem behaviour. A subscale, ‘ADHD symptoms’,
comprisesitems1–3,anditems4and5arecombinedinto
a second subscale, ‘oppositional deﬁant disorder (ODD)
symptoms’. For each period, parents and teachers rate
each item on a four-point scale using the following
values:0 = not atall;1 = justa little;2 = prettymuch;
3 = very much.
4. Kinder Lebensqualita ¨tsfragebogen (KINDL) question-
naire for the assessment of health-related QoL [24]:
This is a short, validated tool comprising 24 items,
with six subscores (physical well-being, emotional
well-being, self-esteem, family, friends and school).
Three different versions were used according to age
group: KID-KINDL (children aged 6–11 years old),
the self-reported KIDDO-KINDL (adolescents aged
12–17 years old) and KINDL for parents of patients
aged 6–17 years old.
Details about these instruments, as well as their use and
results in the OBSEER study, are described elsewhere in
this supplement [3, 8, 25].
Statistical analysis
In a post hoc analysis, internal consistency was assessed
by calculating Cronbach’s alpha. Additionally, part-whole-
corrected correlations were calculated to assess the corre-
lation between item scores and scale scores. Exploratory
principal component analyses with varimax rotation were
conducted to explore the factor structure of the scales. The
stability of ratings was assessed by correlating ratings at
Table 2 Item statistics for patient satisfaction (SAMS-S, n = 552)
Item Mean SD Patients expressing
high satisfaction (%)
Item-total
correlation
1 My medicine helps me reduce the trouble I have 4.87 1.10 74.10 0.73
2 My medicine helps me pay attention 5.07 0.95 80.40 0.71
3 My medicine helps me stay in my seat when I am supposed to 4.85 1.29 71.60 0.57
4 My medicine helps me sustain attention and stick to tasks 5.04 1.01 78.30 0.70
5 My medicine helps me cope better with homework
assignments and other tasks
4.85 1.14 72.10 0.66
6 My medicine helps me get along with other kids 4.69 1.37 65.20 0.57
7 My medicine helps me get along with my family 4.63 1.36 63.60 0.57
8 My medicine helps me get along at school 5.03 1.02 78.10 0.77
9 The effects of my medicine start in good time in the morning 4.98 1.15 75.50 0.62
10 My medicine is effective long enough during the day 4.73 1.33 66.10 0.71
11 My medicine makes me feel good 4.73 1.33 66.10 0.71
12 Overall, I am quite happy with my medicine 5.01 1.20 79.00 0.77
Total score (sum of item scores/12) 4.87 0.87 – –
SAMS Satisfaction with medication, SD Standard deviation
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correlations were computed to assess the relationships
between parent and patient satisfaction and ADHD symp-
toms and QoL at Visit 3 or symptom changes from Visit 1
to Visit 3. Stepwise regression analyses were conducted to
identify predictors for satisfaction with medication.
Results
Parent and patient satisfaction and internal consistency
of the satisfaction scales
The SAMS-P questionnaire was completed by parents for
589 patients (all receiving Equasym XL
) at Visit 3.
Table 1 shows the statistics for each item of the ques-
tionnaire. Means and standard deviations are reported, as
well as the percentage of parents who agreed or strongly
agreed with each statement (i.e. high satisfaction, item
score C 5). The item-total correlation (r) is the part-whole-
corrected correlation of one item with the total scale score
(sum of all 12 items). Over 70% of parents expressed a
high overall satisfaction with the medication (item 12), and
63.0–75.6% agreed or strongly agreed with the ﬁrst eight
items of the questionnaire, which indicates high satisfac-
tion with the effects of the medication on the attention and
behaviour of their children, not only in academic situations,
but also in their social interactions with other children and
within the family. A high rate of satisfaction could also be
found with respect to the onset of the effect of the medi-
cation in the morning (73.0%), while a somewhat lower
rate was observed with the duration of the medication
effect (57.6%). Finally, 57.6% of parents also reported high
satisfaction with how the medication helped their child feel
good. The item-total correlations were in the high range,
from r = 0.71 to r = 0.90, indicating close correlations
between the single item scores and the total scale score.
The internal consistency was also high (Cronbach’s
alpha = 0.96), indicating a good reliability of the scale.
The SAMS-S questionnaire was completed by 552
patients at Visit 3, and the item statistics for patient satis-
faction are shown in Table 2. Overall satisfaction with the
medication (item 12) was high for 79.0% of patients—
slightly more than for parents—and 63.6–80.4% agreed or
strongly agreed with the ﬁrst eight items of the question-
naire. A high rate of satisfaction could also be found with
the onset of the medication effect in the morning (75.5%),
while a somewhat lower rate was observed with the dura-
tion of the medication (66.1%); 66.1% of children also
reported high satisfaction with how the medication helped
them feel good. The item-total correlations were in a
medium-to-high range from r = 0.57 to r = 0.77, indi-
cating good correlations between the single items and the
total scale score. As observed for SAMS-P, the internal
consistency was again high (Cronbach’s alpha = 0.92),
indicating a good reliability of the scale.
Exploratory principal component analyses with varimax
rotation of SAMS-P results revealed only one factor with
an eigenvalue above 1, which explained 71.3% of variance,
indicating that the one-factor solution is the most suitable
for this scale. Conversely, exploratory principal component
analyses of SAMS-S results revealed two factors with
eigenvalues above 1, which explained 66.9% of variance,
while the one-factor solution only explained 54.5% of
variance.
In the two-factor solution, the ﬁrst factor had highest
loadings with items describing effects on attention, cog-
nitive demands and onset and duration of effects (items 2,
4, 5 and 9–12). The second factor comprised satisfaction
regarding hyperactive behaviour and getting along with
others (items 1, 3 and 6–8).
The analysis of rating stability (correlation between rat-
ings at different time points) from Visit 2 to Visit 3 (the two
visits being 3–10 weeks apart from one another) gave a
correlationofr = 0.54(n = 569)forSAMS-Pandr = 0.59
(n = 535) for SAMS-S. Satisfaction with medication
showed a slight, but statistically signiﬁcant (P\0.001)
increasefromVisit2toVisit3forbothSAMS-PandSAMS-S
(Table 3a).
Cross-informant correlations between SAMS-P and
SAMS-S were r = 0.48 at Visit 1 (n = 504), r = 0.50 at
Visit 2 (n = 701) and r = 0.60 at Visit 3 (n = 692),
indicating stable correlations in the medium range across
the three visits. At all three visits, patients reported slightly
higher satisfaction than parents, which was statistically
signiﬁcant (P\0.001, Table 3b).
Prediction of parent and patient satisfaction
Correlation between satisfaction with medication,
ADHD symptoms and QoL at Visit 3
No substantial correlations were found between parent and
patient satisfaction, and patient age or gender or Equasym
XL
 dosage at Visit 3.
We calculated the correlations between SAMS-P and
SAMS-S total scale scores and ratings of ADHD symptoms
at Visit 3 from the OBSEER study, which were obtained
using different ADHD rating scales [8].
Table 4 shows the Pearson’s correlations between sat-
isfaction with medication, and parent and teacher ratings of
ADHD symptoms, of ADHD-related functional impair-
ment and of attentive–reﬂexive and enduring behaviour on
the FBB-ADHD scale [4, 12], physician ratings of ADHD
core symptoms on the CGI-S scale, and parent and teacher
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the DAYAS scale (ADHD symptoms subscale) [3].
The highest correlations were found between parent
ratings of satisfaction and parent ratings of total ADHD
symptoms on the FBB-ADHD scale (r =- 0.60), parent
ratings of impairment due to ADHD symptoms on the
same scale (r =- 0.62) and parent ratings of ADHD
symptoms in the afternoon on the DAYAS scale (r =- 0.54).
As expected, the correlations between parental satisfaction
and teacher (FBB-ADHD and DAYAS) or physician (CGI-
S) ratings of symptoms were weaker, but still substantial.
In general, the correlation between symptom ratings and
patient satisfaction (SAMS-S) was also weaker than the
correlation between the same ratings and parent satisfac-
tion (Table 4). All of the correlations in Table 4, except
for the rating of attentive–reﬂexive and enduring behav-
iour, were negative, indicating lower satisfaction with
medication in children with higher ratings of ADHD
symptoms.
The correlation between satisfaction with medication
and QoL data from the OBSEER study [25] was also
evaluated. Table 5 shows the correlations between satis-
faction (SAMS-P and SAMS-S) and patient QoL (total
QoL and subscales) at Visit 3, as assessed using the
KINDL questionnaire by parents (KINDL), children (KID-
KINDL) or adolescents (KIDDO-KINDL). Parent total
ratings of QoL correlated in the medium range with
parental satisfaction with medication (r = 0.53), indicating
higher parental satisfaction with medication for children
with higher QoL. The correlations between parental satis-
faction and patient (child or adolescent) ratings of QoL
were somewhat lower, but still in the medium range.
Conversely, patient satisfaction with medication showed
highest correlation with child ratings of total QoL
(r = 0.53), while the correlation with parent ratings of
QoL was somewhat lower. Adolescent ratings of QoL
correlated to a similar degree with both parent and patient
satisfaction. All subscales of QoL showed substantial
Table 3 Analysis of (a) rating
stability from Visit 2 to Visit 3
and (b) cross-informant
correlations between SAMS-P
and SAMS-S at each study visit
SAMS Satisfaction with
medication, SD Standard
deviation, *Pvalues refer to
the difference between Visit 2
and Visit 3; ** P values refer to
the difference between SAMS-P
and SAMS-S
Visit 2, mean (SD) Visit 3, mean (SD) r (n) t (t test) P value*
(a) Rating stability
SAMS-P 4.46 (1.03) 4.69 (1.02) 0.54 (569) -5.61 \0.001
SAMS-S 4.75 (0.86) 4.87 (0.87) 0.59 (535) -3.52 \0.001
SAMS-P, mean (SD) SAMS-S, mean (SD) r (n) t (t test) P value**
(b) Cross-informant correlations
Visit 1 4.11 (1.08) 4.38 (0.96) 0.48 (504) -5.84 \0.001
Visit 2 4.39 (1.08) 4.67 (0.92) 0.50 (701) -7.36 \0.001
Visit 3 4.61 (1.07) 4.78 (0.93) 0.60 (692) -4.98 \0.001
Table 4 Pearson’s correlations between parent and patient satisfaction with medication (SAMS-P and SAMS-S) and ratings of ADHD
symptoms at Visit 3
Variable SAMS-P r (n) SAMS-S r (n)
Parent ratings of ADHD symptoms (FBB-ADHD-total) -0.60 (716) -0.38 (693)
Parent ratings of impairment due to ADHD symptoms (FBB-ADHD-impairment) -0.62 (719) -0.40 (696)
Parent ratings of attentive–reﬂexive and enduring behaviour (FBB-ADHD-attention-reﬂexivity) 0.42 (718) 0.29 (695)
Teacher ratings of ADHD symptoms (FBB-ADHD-total) -0.34 (545) -0.30 (536)
Teacher ratings of impairment due to ADHD symptoms (FBB-ADHD-impairment) -0.33 (545) -0.29 (536)
Teacher ratings of attentive–reﬂexive and enduring behaviour (FBB-ADHD-attention-reﬂexivity) 0.21 (542) 0.19 (533)
Clinical Global Impression (CGI) -0.31 (691) -0.25 (683)
Parent ratings of ADHD symptoms in the morning (DAYAS-P-ADHD-morning) -0.22 (718) -0.19 (718)
Parent ratings of ADHD symptoms in the afternoon (DAYAS-P-ADHD-afternoon) -0.54 (712) -0.31 (697)
Parent ratings of ADHD symptoms in the late afternoon (DAYAS-P-ADHD-late afternoon) -0.44 (719) -0.26 (703)
Parent ratings of ADHD symptoms in the evening (DAYAS-P-ADHD-evening) -0.34 (718) -0.22 (702)
Teacher ratings of ADHD symptoms in the ﬁrst half of school morning (DAYAS-T-ADHD-ﬁrst half) -0.29 (574) -0.27 (567)
Teacher ratings of ADHD symptoms in the second half of school morning (DAYAS-T-ADHD-second half) -0.28 (573) -0.23 (566)
All correlations are statistically signiﬁcant at P B 0.001
CGI Clinical global impression, DAYAS Day proﬁle of ADHD symptoms, FBB-ADHD Fremdbeurteilungsbogen fu ¨r Aufmerksamkeitsdeﬁzit-
Hyperaktivita ¨tssto ¨rung
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indicating that QoL in all domains contributes signiﬁcantly
to satisfaction with medication.
Subsequently, we conducted stepwise regression analy-
ses with teacher and parent ratings of ADHD symptoms
(FBB-ADHD total), ADHD-related functional impairment
and attentive–reﬂexive and enduring behaviour on the
FBB-ADHD scale, parental ratings of ADHD symptoms
(items 1–3) and ODD symptoms (items 4–5) in the after-
noon on the DAYAS scale, and parent (KINDL total score)
and patient (KID-KINDL total score) ratings of QoL as
predictors.
Criteria were parent and patient satisfaction with med-
ication. In the stepwise regression analyses for parental
satisfaction with medication, in a sample of 327 patients
with all data present, four variables entered the ﬁnal
equation: (1) parent rating of impairment due to ADHD
symptoms (FBB-ADHD-impairment), (2) parent rating of
attentive–reﬂexive and enduring behaviour (FBB-ADHD-
attention-reﬂexivity), (3) parent rating of ADHD symptoms
in the afternoon on the DAYAS and (4) parent rating of
QoL (KINDL total score). The multiple correlation of these
four predictors with parent satisfaction was R = 0.72,
which explained 52.3% of the variance (corrected R
2)o f
parent satisfaction. All other potential predictors did not
increase the variance in a statistically signiﬁcant manner.
In the stepwise regression analyses for patient satisfaction
with medication, in a sample of 321 patients with all data
present, four variables entered the ﬁnal equation: (1)
patient rating of QoL (KID-KINDL total score), (2) parent
rating of ODD symptoms in the afternoon on the DAYAS,
(3) parent rating of attentive–reﬂexive and enduring
behaviour (FBB-ADHD-attention-reﬂexivity) and (4) tea-
cher rating of ADHD symptoms (FBB-ADHD-total). The
multiple correlation of these four predictors with patient
satisfaction was R = 0.61, which explained 36.4% of the
variance (corrected R
2) of patient satisfaction. All other
potential predictors did not increase the variance in a sta-
tistically signiﬁcant manner.
Correlation between satisfaction with medication
at Visit 3, and changes in ADHD symptoms and QoL
from Visit 1 to Visit 3
Satisfaction with medication was also evaluated in relation
to changes over time in ADHD symptoms and QoL, as
assessed in the OBSEER study [8, 25]. Table 6 shows the
correlations between satisfaction with medication and the
reductions from Visit 1 to Visit 3 in parent and teacher
ratings of ADHD symptoms (FBB-ADHD-total), attention-
reﬂexivity and functional impairment on the FBB-ADHD
scale [4, 12], physician ratings of ADHD core symptoms
on the CGI-S scale and parent and teacher ratings of
ADHD symptoms at different times of the day on the
DAYAS scale (ADHD symptoms subscale) [3].
The highest correlations were found between parental
satisfaction and the reductions in parent-rated ADHD
symptoms on the FBB-ADHD scale (r = 0.43), in parent-
rated functional impairment on the same rating scale
(r = 0.44) and in parent-rated ADHD symptoms in the
afternoon on the DAYAS (r = 0.40). This indicates higher
parent satisfaction for children showing a greater reduction
in ADHD symptoms. As expected, the correlation between
parent satisfaction and changes in teacher ratings of
symptoms and in physician ratings of change on the CGI-I
scale was lower, although still substantial. In general, the
correlation of a given measure with patient satisfaction
Table 5 Pearson’s correlations between parent and patient satisfac-
tion with medication (SAMS-P and SAMS-S) and ratings of QoL at
Visit 3
Variable SAMS-P r (n) SAMS-S r (n)
QoL total
Parent rating 0.53 (627) 0.38 (608)
Child rating 0.45 (448) 0.53 (446)
Adolescent rating 0.37 (167) 0.39 (171)
QoL physical well-being
Parent rating 0.29 (638) 0.22 (619)
Child rating 0.37 (454) 0.35 (452)
Adolescent rating 0.23 (170) 0.26 (174)
QoL emotional well-being
Parent rating 0.37 (637) 0.27 (618)
Child rating 0.25 (454) 0.31 (452)
Adolescent rating 0.22 (170) 0.23 (174)
QoL self
Parent rating 0.47 (634) 0.35 (615)
Child rating 0.37 (454) 0.42 (452)
Adolescent rating 0.24 (170) 0.35 (174)
QoL family
Parent rating 0.47 (637) 0.30 (615)
Child rating 0.31 (454) 0.37 (452)
Adolescent rating 0.34 (170) 0.26 (174)
QoL friends
Parent rating 0.32 (633) 0.23 (614)
Child rating 0.27 (451) 0.33 (449)
Adolescent rating 0.17 (168) 0.28 (172)
QoL school
Parent rating 0.40 (629) 0.27 (610)
Child rating 0.29 (449) 0.43 (447)
Adolescent rating 0.35 (167) 0.29 (171)
All correlations are statistically signiﬁcant at P B 0.05
Parent ratings used the Kinder Lebensqualita ¨tsfragebogen (KINDL)
scale, child ratings the KID-KINDL scale and adolescent ratings the
KIDDO-KINDL scale
QoL Quality of life, SAMS Satisfaction with medication
Eur Child Adolesc Psychiatry (2011) 20 (Suppl 2):S297–S307 S303
123(SAMS-S) was also lower than the correlation between the
same measure and parent satisfaction (SAMS-P, Table 6).
Table 7 shows the correlations between satisfaction with
medication and improvements in patient QoL from Visit 1
to Visit 3, as rated by parents (KINDL), children
(KID-KINDL) and adolescents (KIDDO-KINDL). The
improvement in parent ratings of total patient QoL corre-
lated with parent satisfaction with medication (SAMS-P) in
the low to medium range (r = 0.39), indicating that
parental satisfaction is higher for children with greater
improvements in QoL. The correlations between
improvements in child or adolescent ratings of QoL and
parent satisfaction were in the same range. Patient satis-
faction with medication (SAMS-S) showed the highest
correlation with improvements in patient ratings of QoL
(KID-KINDL and KIDDO-KINDL), while the correlation
with improvements in parent rating was somewhat lower.
Table 7 also shows that all subscales of QoL correlated
with parent and patient satisfaction with medication, indi-
cating that improvements in all QoL domains contribute to
satisfaction with medication; however, not all these cor-
relations were statistically signiﬁcant.
We then conducted stepwise regression analyses with
changes between Visit 1 and Visit 3 in teacher and parent
ratings of ADHD symptoms (FBB-ADHD-total), functional
impairment (FBB-ADHD-impairment) and attentive–
reﬂexive and enduring behaviour (FBB-ADHD-attention-
reﬂexivity) on the FBB-ADHD scale, changes in parental
ratingsofADHDandODDsymptomsintheafternoononthe
DAYAS and changes in parent and patient ratings of QoL
(KINDL-total and KID-KINDL-total) as predictors.
Criteria were parent and patient satisfaction with med-
ication. In the stepwise regression analysis for parental
satisfaction with medication, in a sample of 255 patients
with all data present, three variables entered the ﬁnal
equation: improvement in (1) parent ratings of functional
impairment (FBB-ADHD-impairment), (2) parent ratings
of attentive–reﬂexive and enduring behaviour (FBB-
ADHD-attention-reﬂexivity) and (3) parent rating of QoL
(KINDL-total). The multiple correlation of these three
predictors with parent satisfaction was R = 0.58, which
explained 33.0% of the variance (corrected R
2) of parent
satisfaction. All other potential predictors did not increase
the variance in a statistically signiﬁcant manner. Similarly,
in the stepwise regression analysis for patient satisfaction
with medication, in a sample of 253 patients with all data
present, three variables entered the ﬁnal equation:
improvement in (1) patient ratings of QoL (KID-KINDL-
total), (2) parent ratings of attentive–reﬂexive and enduring
behaviour (FBB-ADHD-attention-reﬂexivity) and (3)
functional impairment (FBB-ADHD-impairment). The
multiple correlation of these three predictors with patient
satisfaction was R = 0.44, which explained 17.9% of the
variance (corrected R
2) of patient satisfaction. All other
potential predictors did not increase the variance in a sta-
tistically signiﬁcant manner.
Discussion
Satisfaction with medication is an important factor in the
evaluation of treatment outcome and is predictive of better
Table 6 Pearson’s correlations between parent and patient satisfaction with medication (SAMS-P and SAMS-S) and reduction in ADHD
symptoms from Visit 1 to Visit 3
Variable SAMS-P
r (n)
SAMS-S
r (n)
Reduction of parent-rated ADHD symptoms (FBB-ADHD-total) 0.43 (691) 0.28 (670)
Reduction of parent-rated impairment due to ADHD symptoms (FBB-ADHD-impairment) 0.44 (690) 0.31 (670)
Increase in parent-rated attentive–reﬂexive and enduring behaviour (FBB-ADHD-attention-reﬂexivity) 0.35 (691) 0.27 (670)
Reduction of teacher-rated ADHD symptoms (FBB-ADHD-total) 0.27 (499) 0.25 (495)
Reduction of teacher-rated impairment due to ADHD symptoms (FBB-ADHD-impairment) 0.28 (499) 0.27 (495)
Increase in teacher-rated attentive–reﬂexive and enduring behaviour (FBB-ADHD-attention-reﬂexivity) 0.25 (491) 0.25 (487)
Improvement in Clinical Global Impression (CGI) 0.25 (629) 0.22 (626)
Reduction in parent-rated ADHD symptoms in the morning (DAYAS-P-ADHD-morning) 0.24 (680) 0.16 (667)
Reduction in parent-rated ADHD symptoms in the afternoon (DAYAS-P-ADHD-afternoon) 0.40 (669) 0.23 (659)
Reduction in parent-rated ADHD symptoms in the late afternoon (DAYAS-P-ADHD-late afternoon) 0.34 (680) 0.17 (668)
Reduction in parent-rated ADHD symptoms in the evening (DAYAS-P-ADHD-evening) 0.24 (678) 0.12 (666)
Reduction in teacher-rated ADHD symptoms in the ﬁrst half of school morning (DAYAS-T-ADHD-ﬁrst half) 0.23 (530) 0.25 (528)
Reduction in teacher-rated ADHD symptoms in the second half of school morning (DAYAS-T-ADHD-second half) 0.23 (509) 0.25 (506)
All correlations are statistically signiﬁcant at P B 0.001
DAYAS Day proﬁle of ADHD symptoms, FBB-ADHD Fremdbeurteilungsbogen fu ¨r Aufmerksamkeitsdeﬁzit-Hyperaktivita ¨tssto ¨rung
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123adherence and compliance [20]. In this analysis of satis-
faction data collected using the SAMS questionnaire, we
show that satisfaction with Equasym XL
 among parents
and children enrolled in the OBSEER trial was high, with
rates of overall satisfaction reaching 70.5 and 79.0%,
respectively. This is in agreement with the results of pre-
vious studies with stimulant medications [7, 10, 11, 28, 29].
Approximately 30% of parents were dissatisﬁed with the
medication. While efﬁcacy was highly rated, approxi-
mately half of parents and patients were recorded as not
satisﬁed with the duration of action of Equasym XL
 (item
10 of the SAMS questionnaire). This result highlights the
importance of treatment individualisation and the need for
multiple treatment options to give parents and patients
more choice.
With respect to the psychometric properties of the
SAMS tool, the item-total correlation was high for all items
in the parent version (SAMS-P) of the questionnaire
(r = 0.71–0.90) and medium–high for the patient version
(SAMS-S, r = 0.57–0.77). Internal consistency was also
high for both SAMS-P and SAMS-S, with Cronbach’s
alpha values[0.9. Principal component analyses showed
that the one-factor solution best ﬁt the SAMS data,
explaining a high percentage ([71%) of variance; together
with the high internal consistency of the scale, this further
emphasises the adequacy of the SAMS total score for
describing satisfaction with medication. The analysis of the
stability of ratings (correlation between the same rating at
different time points) revealed correlations in the medium
range between Visit 2 and Visit 3, indicating a moderate
stability of satisfaction with medication for both parents
and patients (r = 0.54 and 0.59, respectively). Cross-
informant rating correlations at each visit were also mod-
erate (r = 0.48–0.60), underlining the importance of
assessing the perspectives of both patients and parents.
In the analysis of predictors of satisfaction at the end of
the study (Visit 3), the highest correlations (r =- 0.62 to
-0.54) were found between parent satisfaction and parent
rating of ADHD symptoms and impairment (FBB-ADHD
scale) and of ADHD symptoms in the afternoon (DAYAS
scale) at Visit 3; as expected, correlations between satis-
faction and ADHD symptoms were negative, indicating
lower satisfaction with medication in children with higher
ratings of symptoms. Regarding QoL at Visit 3, the highest
correlations (r = 0.53) were observed between parent sat-
isfaction and parent overall ratings of QoL and between
patient satisfaction and patient overall ratings of QoL;
correlations in the case of QoL were positive, indicating
higher satisfaction with medication in patients with better
QoL. Stepwise regression analyses for parental satisfaction
with medication at Visit 3 showed that parental satisfaction
could be explained to a high degree ([52% of variance) by
four variables, which mainly reﬂected ADHD impairment
and ADHD symptoms (three variables), but also QoL (one
variable). The explained variance in the regression analysis
for patient satisfaction was somewhat lower (36% of var-
iance explained), but still substantial. As in the case of
parents, four variables contributed signiﬁcantly to the
prediction of patient satisfaction and included patient rat-
ings related to QoL (one variable) along with parent ratings
of ODD symptoms and attentive–reﬂexive and enduring
behaviour as well as teacher ratings of ADHD symptoms.
When satisfaction with medication was evaluated in
relation to changes in ADHD symptoms during the study
from baseline (Visit 1) to the end of the study (Visit 3), the
highest correlations were found between parent satisfaction
Table 7 Pearson’s correlations between parent and patient satisfac-
tion with medication (SAMS-P and SAMS-S) and improvement in
QoL from Visit 1 to Visit 3
Visit 1 to Visit 3 improvement SAMS-P r (n) SAMS-S r (n)
QoL total
Parent rating 0.39 (593) 0.22 (577)
Child rating 0.38 (430) 0.31 (428)
Adolescent rating 0.33 (148) 0.30 (151)
QoL physical well-being
Parent rating 0.16 (612) 0.12 (596)
Child rating 0.26 (443) 0.19 (441)
Adolescent rating 0.12 (154)
ns 0.14 (157)
ns
QoL emotional well-being
Parent rating 0.27 (611) 0.13 (595)
Child rating 0.20 (443) 0.19 (441)
Adolescent rating 0.24 (154) 0.12 (157)
ns
QoL self
Parent rating 0.34 (607) 0.20 (591)
Child rating 0.27 (442) 0.23 (440)
Adolescent rating 0.21 (154) 0.30 (157)
QoL family
Parent rating 0.31 (607) 0.17 (591)
Child rating 0.25 (440) 0.22 (438)
Adolescent rating 0.21 (153) 0.12 (156)
ns
QoL friends
Parent rating 0.23 (606) 0.15 (590)
Child rating 0.26 (438) 0.23 (436)
Adolescent rating 0.34 (151) 0.36 (154)
QoL school
Parent rating 0.28 (596) 0.15 (580)
Child rating 0.26 (434) 0.20 (432)
Adolescent rating 0.19 (149) 0.14 (152)
ns
All correlations are statistically signiﬁcant at P B 0.05, except those
marked
ns
Parent ratings used the Kinder Lebensqualita ¨tsfragebogen (KINDL)
scale, child ratings the KID-KINDL scale and adolescent ratings the
KIDDO-KINDL scale
QoL Quality of life, SAMS Satisfaction with medication
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123and the same ratings that showed highest correlation at the
end of the study (r = 0.40–0.44). Regarding QoL, the
highest correlations were observed between parent satis-
faction and parent ratings of QoL (r = 0.39); correlations
between parent satisfaction and patient ratings and between
patient satisfaction and patient ratings were in the same
range (r = 0.30–0.38). Stepwise regression analyses
showed that changes in symptom ratings from Visit 1 to
Visit 3 could explain satisfaction with medication, but to a
lesser degree compared with symptom ratings at Visit 3
(33% of variance for parents and 17% for patients). Taken
together, these analyses show that symptom severity and/or
functional impairment at the end of the study, as well as
QoL, are the most signiﬁcant predictors for parent and
patient satisfaction, underscoring the importance of func-
tional impairment and QoL, besides ADHD symptoms, as
outcome parameters in the treatment of children with
ADHD.
One of the recognised limitations of observational
studies is that inclusion and exclusion criteria are not as
rigorous as in clinical trials, and treatment conditions (e.g.
dosing) are less controlled and standardised. However,
these features of observational trials can at the same time
represent an advantage, as they reﬂect routine care condi-
tions in the real population. In particular, for satisfaction
with medication, ratings from clinical trials are less infor-
mative as they are inﬂuenced by the fact that the sample is
likely to be biased, given that those who agree to partici-
pate in the studies tend to do so because they are not sat-
isﬁed with their previous medication [5].
In conclusion, these results show that parent and patient
satisfaction can be assessed reliably with the new SAMS-P
and SAMS-S questionnaires. It is important to assess the
perspectives of parents and patients separately, with rating
scales asking comparable questions, as their perceptions of
medication are correlated, but only to a medium degree.
Both symptom severity at the end of the study and symp-
tom reduction during treatment have a strong inﬂuence on
parent and patient satisfaction; however, functional
impairment and QoL at the end of the study as well as their
improvement during treatment are also important factors
and should be taken into consideration.
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